Dynamics of Mutator and Antibiotic-Resistant Populations in a Pharmacokinetic/Pharmacodynamic Model of Pseudomonas aeruginosa Biofilm Treatment

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Antimicrobial Agents and Chemotherapy

• Publication date

  2011-08-22

• Fields of study

  Biology, Medicine, Environmental Science

• Identifiers
  DOI 10.1128/AAC.00617-11PMID 21859941PMCID PMC3195006
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Evolutionary dynamics of bacteria in a human host environment

  2011cited by this paper
• Overexpression of AmpC and Efflux Pumps in Pseudomonas aeruginosa Isolates from Bloodstream Infections: Prevalence and Impact on Resistance in a Spanish Multicenter Study

  2011cited by this paper
• Antagonistic Interactions of Pseudomonas aeruginosa Antibiotic Resistance Mechanisms in Planktonic but Not Biofilm Growth

  2011cited by this paper
• Efficacy of the Combination of Tobramycin and a Macrolide in an InVitroPseudomonas aeruginosa Mature Biofilm Model

  2010cited by this paper
• [Pseudomonas aeruginosa in chronic obstructive pulmonary disease].

  2010cited by this paper
• An update on Pseudomonas aeruginosa biofilm formation, tolerance, and dispersal.

  2010cited by this paper
• Anti-biofilm and resistance suppression activities of CXA-101 against chronic respiratory infection phenotypes of Pseudomonas aeruginosa strain PAO1.

  2010cited by this paper
• Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aeruginosa.

  2010cited by this paper
• Azithromycin in Pseudomonas aeruginosa Biofilms: Bactericidal Activity and Selection of nfxB Mutants

  2009cited by this paper
• Role of Mutation in Pseudomonas aeruginosa Biofilm Development

  2009cited by this paper
• Novel in vitro pharmacodynamic model simulating ofloxacin pharmacokinetics in the treatment of Pseudomonas aeruginosa biofilm-associated infections.

  2009cited by this paper
• Endogenous oxidative stress produces diversity and adaptability in biofilm communities

  2008cited by this paper
• Tolerance to the antimicrobial peptide colistin in Pseudomonas aeruginosa biofilms is linked to metabolically active cells, and depends on the pmr and mexAB‐oprM genes

  2008cited by this paper
• Resistance and Virulence of Pseudomonas aeruginosa Clinical Strains Overproducing the MexCD-OprJ Efflux Pump

  2008cited by this paper
• Evolutionary biology of bacterial and fungal pathogens

  2008cited by this paper
• Biofilm Induced Tolerance towards Antimicrobial Peptides

  2008cited by this paper
• Evolution of Pseudomonas aeruginosa pathogenicity: from acute to chronic infections.

  2008cited by this paper
• Pseudomonas aeruginosa in chronic obstructive pulmonary disease.

  2008cited by this paper
• Increased mutability of Pseudomonas aeruginosa in biofilms.

  2008cited by this paper
• Genetic Adaptation of Pseudomonas aeruginosa to the Airways of Cystic Fibrosis Patients Is Catalyzed by Hypermutation

  2008cited by this paper
• Chronic Pseudomonas aeruginosa infection in chronic obstructive pulmonary disease.

  2008cited by this paper
• Dynamics of Pseudomonas aeruginosa genome evolution

  2008cited by this paper
• Involvement of a Novel Efflux System in Biofilm-Specific Resistance to Antibiotics

  2008cited by this paper
• Pharmacokinetics and pharmacodynamics of antimicrobials.

  2007cited by this paper
• Inactivation of the Mismatch Repair System in Pseudomonas aeruginosa Attenuates Virulence but Favors Persistence of Oropharyngeal Colonization in Cystic Fibrosis Mice

  2007cited by this paper
• Resistance Mechanisms of Multiresistant Pseudomonas aeruginosa Strains from Germany and Correlation with Hypermutation

  2007cited by this paper
• Influence of High Mutation Rates on the Mechanisms and Dynamics of In Vitro and In Vivo Resistance Development to Single or Combined Antipseudomonal Agents

  2007cited by this paper
• Levofloxacin pharmacokinetics in adult cystic fibrosis.

  2007cited by this paper
• Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore.

  2007cited by this paper
• Multiple sensors control reciprocal expression of Pseudomonas aeruginosa regulatory RNA and virulence genes.

  2006cited by this paper
• Efficacy and Potential for Resistance Selection of Antipseudomonal Treatments in a Mouse Model of Lung Infection by Hypermutable Pseudomonas aeruginosa

  2006cited by this paper
• Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients.

  2006cited by this paper
• Occurrence of Hypermutable Pseudomonas aeruginosa in Cystic Fibrosis Patients Is Associated with the Oxidative Stress Caused by Chronic Lung Inflammation

  2005cited by this paper
• Bacterial-population responses to drug-selective pressure: examination of garenoxacin's effect on Pseudomonas aeruginosa.

  2005cited by this paper
• Hypermutation Is a Key Factor in Development of Multiple-Antimicrobial Resistance in Pseudomonas aeruginosa Strains Causing Chronic Lung Infections

  2005influential reference
• Overexpression of the Multidrug Efflux Pumps MexCD-OprJ and MexEF-OprN Is Associated with a Reduction of Type III Secretion in Pseudomonas aeruginosa

  2005cited by this paper
• Hypermutation and the Preexistence of Antibiotic-Resistant Pseudomonas aeruginosa Mutants: Implications for Susceptibility Testing and Treatment of Chronic Infections

  2004cited by this paper
• Issues in Pharmacokinetics and Pharmacodynamics of Anti-Infective Agents: Kill Curves versus MIC

  2004cited by this paper
• Lack of Association between Hypermutation and Antibiotic Resistance Development in Pseudomonas aeruginosa Isolates from Intensive Care Unit Patients

  2004cited by this paper
• Cell Death in Pseudomonas aeruginosa Biofilm Development

  2003cited by this paper
• Biofilm formation by Pseudomonas aeruginosa wild type, flagella and type IV pili mutants

  2003cited by this paper
• Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy.

  2003cited by this paper
• Pathophysiology and management of pulmonary infections in cystic fibrosis.

  2003cited by this paper
• The mutant selection window and antimicrobial resistance.

  2003influential reference
• A genetic basis for Pseudomonas aeruginosa biofilm antibiotic resistance

  2003cited by this paper
• Antimicrobial resistance of Pseudomonas aeruginosa biofilms.

  2003cited by this paper
• Role of Efflux Pumps and Mutations in Genes for Topoisomerases II and IV in Fluoroquinolone-Resistant Pseudomonas aeruginosa Strains

  2003cited by this paper
• Journal of Antimicrobial Chemotherapy

  2002cited by this paper
• The mismatch repair system (mutS, mutL and uvrD genes) in Pseudomonas aeruginosa: molecular characterization of naturally occurring mutants

  2002cited by this paper
• Lung Infections Associated with Cystic Fibrosis

  2002cited by this paper
• Pseudomonas aeruginosa and the in vitro and in vivo biofilm mode of growth.

  2001cited by this paper
• Mechanisms of biofilm resistance to antimicrobial agents.

  2001cited by this paper
• Quantification of biofilm structures by the novel computer program COMSTAT.

  2000influential reference
• Pharmacodynamic Modeling of Risk Factors for Ciprofloxacin Resistance in Pseudomonas aeruginosa

  2000cited by this paper
• High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection.

  2000influential reference
• Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen

  2000cited by this paper
• Molecular Mechanisms of Fluoroquinolone Resistance in Pseudomonas aeruginosa Isolates from Cystic Fibrosis Patients

  2000cited by this paper
• Heterogeneity in biofilms.

  2000cited by this paper
• Molecular tools for study of biofilm physiology.

  1999cited by this paper
• Bacterial biofilms: a common cause of persistent infections.

  1999cited by this paper
• Pharmacodynamic Evaluation of Factors Associated with the Development of Bacterial Resistance in Acutely Ill Patients during Therapy

  1998cited by this paper
• Mechanisms of Quinolone Resistance in Clinical Strains of Pseudomonas aeruginosa

  1998cited by this paper
• Spatial Physiological Heterogeneity inPseudomonas aeruginosa Biofilm Is Determined by Oxygen Availability

  1998cited by this paper
• Role of mutator alleles in adaptive evolution

  1997cited by this paper
• Evolution of high mutation rates in experimental populations of E. coli

  1997cited by this paper
• Proliferation of mutators in A cell population

  1997cited by this paper
• Lung function in bronchiectasis: the influence of Pseudomonas aeruginosa.

  1996cited by this paper
• Quantitative correlation between susceptibility and OprJ production in NfxB mutants of Pseudomonas aeruginosa

  1996cited by this paper
• Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients

  1993cited by this paper
• Occurrence of the nfxB type mutation in clinical isolates of Pseudomonas aeruginosa

  1992cited by this paper
• Interaction of biofilm bacteria with antibiotics in a novel in vitro chemostat system

  1989cited by this paper
• Selection for high mutation rates in chemostats.

  1974cited by this paper
• Genetic recombination in Pseudomonas aeruginosa.

  1955cited by this paper

• Collateral susceptibility-guided alternation of ceftolozane/tazobactam with imipenem prevents resistance development in XDR Pseudomonas aeruginosa biofilms

  2024cites this paper
• Role of small molecules and nanoparticles in effective inhibition of microbial biofilms: A ray of hope in combating microbial resistance.

  2024cites this paper
• Molecular basis of the phenotypic variants arising from a Pseudoalteromonas lipolytica mutator

  2023cites this paper
• Natural and synthetic molecules with potential to enhance biofilm formation and virulence properties in Pseudomonas aeruginosa

  2023cites this paper
• New insights into the inhibitory roles and mechanisms of D-amino acids in bacterial biofilms in medicine, industry, and agriculture.

  2022cites this paper
• Polygenic adaptation, clonal interference, and the evolution of mutators in experimental Pseudomonas aeruginosa populations

  2021cites this paper
• In Vitro Antimicrobial Susceptibility Testing of Biofilm-Growing Bacteria: Current and Emerging Methods.

  2021cites this paper
• Polygenic Adaptation and Clonal Interference Enable Sustained Diversity in Experimental Pseudomonas aeruginosa Populations

  2021cites this paper
• Ecthyma gangrenosum: The critical role of biofilms and other mechanisms of antibiotic resistance and implications for management

  2021cites this paper
• Tolerance and Persistence of Pseudomonas aeruginosa in Biofilms Exposed to Antibiotics: Molecular Mechanisms, Antibiotic Strategies and Therapeutic Perspectives

  2020cites this paper
• The evolutionary trajectories of P. aeruginosa in biofilm and planktonic growth modes exposed to ciprofloxacin: beyond selection of antibiotic resistance

  2020cites this paper
• Pulse Dosing of Antibiotic Enhances Killing of a Staphylococcus aureus Biofilm

  2020cites this paper
• The evolution of bacterial pathogens in the Anthropocene.

  2020cites this paper
• Effect of Mulberry Leaf Extract on Clinical Isolated Pseudomonas aeruginosa Biofilm Formation

  2020cites this paper
• Tolerance and Resistance of Pseudomonas aeruginosa Biofilms to Antimicrobial Agents—How P. aeruginosa Can Escape Antibiotics

  2019cites this paper
• Effect of trans-Cinnamaldehyde on Methicillin-Resistant Staphylococcus aureus Biofilm Formation: Metabolic Activity Assessment and Analysis of the Biofilm-Associated Genes Expression

  2019cites this paper
• Efficacy of a ciprofloxacin/amikacin combination against planktonic and biofilm cultures of susceptible and low-level resistant Pseudomonas aeruginosa.

  2019cites this paper
• Social Behavior of Antibiotic Resistant Mutants Within Pseudomonas aeruginosa Biofilm Communities

  2019cites this paper
• panish Consensus on the Prevention and Treatment of Pseudomonas eruginosa Bronchial Infections in Cystic Fibrosis Patients

  2018cites this paper
• In vitro and In vivo characterization of anti-biofilm activity of LpxC inhibitor alone, and in combination with different classes of antimicrobials

  2018cites this paper
• Microbiological diagnosis of biofilm-related infections

  2018cites this paper
• Multiscale Evolutionary Dynamics of Host-Associated Microbiomes.

  2018cites this paper
• Evolution of Antibiotic Resistance in Biofilm and Planktonic Pseudomonas aeruginosa Populations Exposed to Subinhibitory Levels of Ciprofloxacin

  2018cites this paper
• Population Pharmacokinetic Modeling as a Tool To Characterize the Decrease in Ciprofloxacin Free Interstitial Levels Caused by Pseudomonas aeruginosa Biofilm Lung Infection in Wistar Rats

  2017cites this paper
• SENSITIVITY TO CIPROFLOXACIN OF PSEUDOMONAS AERUGINOSA STRAINS WITH DIFFERENT LEVELS OF C-DI-GMP BIOSYNTHESIS

  2017cites this paper
• Phenotypic shift in Pseudomonas aeruginosa populations from cystic fibrosis lungs after 2-week antipseudomonal treatment.

  2017cites this paper
• Microbiological diagnosis of biofilm-related infections.

  2017cites this paper
• Insights into the evolution of the mutational resistome of Pseudomonas aeruginosa in cystic fibrosis.

  2017cites this paper
• Spatial Organization Plasticity as an Adaptive Driver of Surface Microbial Communities

  2017cites this paper
• Antibacterial and anti-biofilm activity of novel marine natural product mimics

  2017cites this paper
• Epidemiology of antimicrobial resistance in commensal E. coli : focus on selection and spread of fluoroquinolone resistance in broilers

  2017influential citation
• Studying the effect of administration route and treatment dose on the selection of enrofloxacin resistance in commensal Escherichia coli in broilers

  2017cites this paper
• Antibiotic treatment of biofilm infections

  2017cites this paper
• Sequential Treatment of Biofilms with Aztreonam and Tobramycin Is a Novel Strategy for Combating Pseudomonas aeruginosa Chronic Respiratory Infections

  2016cites this paper
• Relative contribution of biological variation and technical variables to zone diameter variations of disc diffusion susceptibility testing.

  2016cites this paper
• Real-Time Monitoring of nfxB Mutant Occurrence and Dynamics in Pseudomonas aeruginosa Biofilm Exposed to Subinhibitory Concentrations of Ciprofloxacin

  2016cites this paper
• Antimicrobial Blue Light Inactivation of Gram-Negative Pathogens in Biofilms: In Vitro and In Vivo Studies.

  2016cites this paper
• The problems of antibiotic resistance in cystic fibrosis and solutions

  2015cites this paper
• Antibiotic penetration and bacterial killing in a Pseudomonas aeruginosa biofilm model.

  2015cites this paper
• The Challenge of Efflux-Mediated Antibiotic Resistance in Gram-Negative Bacteria

  2015cites this paper
• Contribution of Stress Responses to Antibiotic Tolerance in Pseudomonas aeruginosa Biofilms

  2015cites this paper
• Spanish consensus on the prevention and treatment of Pseudomonas aeruginosa bronchial infections in cystic fibrosis patients.

  2015cites this paper
• Biofilm-specific antibiotic tolerance and resistance

  2015cites this paper
• Scaffold-based Anti-infection Strategies in Bone Repair

  2015cites this paper
• Spanish consensus on the prevention and treatment of Pseudomonas aeruginosa bronchial infections in cystic fibrosis patients

  2015cites this paper
• Consenso español para la prevención y el tratamiento de la infección bronquial por Pseudomonas aeruginosa en el paciente con fibrosis quística

  2015cites this paper
• Pharmacokinetics and Pharmacodynamics of Aerosolized Antibacterial Agents in Chronically Infected Cystic Fibrosis Patients

  2014cites this paper
• Antibiotic resistance in Pseudomonas aeruginosa biofilms: towards the development of novel anti-biofilm therapies.

  2014cites this paper
• INVOLVEMENT OF REGULATORY NON-CODING RNA IN MOTILITY, BIOFILM FORMATION AND ADAPTIVE RESISTANCE IN PSEUDOMONAS AERUGINOSA by

  2014cites this paper
• Antimicrobial susceptibility testing in biofilm-growing bacteria.

  2014influential citation
• Biofilm Microenvironment Analysis Systems for Medicine and Agriculture

  2014influential citation
• aeruginosaEvolution of Pseudomonas Ciprofloxacin Resistance during Long-Term Rapid Development of High-Level Sublethal Ciprofloxacin Treatment Leads to

  2014cites this paper
• Proteomic analysis of Staphylococcus aureus biofilm cells grown under physiologically relevant fluid shear stress conditions

  2014cites this paper
• Applying insights from biofilm biology to drug development — can a new approach be developed?

  2013cites this paper
• rapid development of high-level ciprofloxacin

  2013cites this paper
• Biofilm Formation Inhibition of Multidrug-Resistant of Clinical Isolates Pseudomonas aeruginosa by Lactoferrin

  2013cites this paper
• Dynamic dosing assay relating real-time respiration responses of Staphylococcus aureus biofilms to changing microchemical conditions.

  2013cites this paper
• Impact of Helicobacter pylori Biofilm Formation on Clarithromycin Susceptibility and Generation of Resistance Mutations

  2013cites this paper
• Sublethal Ciprofloxacin Treatment Leads to Rapid Development of High-Level Ciprofloxacin Resistance during Long-Term Experimental Evolution of Pseudomonas aeruginosa

  2013cites this paper
• Saccharomyces cerevisiae--a model to uncover molecular mechanisms for yeast biofilm biology.

  2012cites this paper
• Biofilm-specific antibiotic resistance.

  2012cites this paper
• Phenotypes selected during chronic lung infection in cystic fibrosis patients: implications for the treatment of Pseudomonas aeruginosa biofilm infections.

  2012cites this paper
• Use of antimicrobial agents in livestock.

  2012cites this paper
• Evolution and Adaptation in Pseudomonas aeruginosa Biofilms Driven by Mismatch Repair System-Deficient Mutators

  2011cites this paper